Cinacalcet in peritoneal dialysis patients: one-center experience
Abstract Introduction: Secondary hyperparathyroidism is the target of several therapeutic strategies, including the use of cinacalcet. Most studies were done only in hemodialysis patients, with few data from peritoneal dialysis patients. Objective: The aim of our work was to evaluate the effective...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Nefrologia
|
| Series: | Brazilian Journal of Nephrology |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002017000100042&lng=en&tlng=en |
| _version_ | 1828524402475532288 |
|---|---|
| author | Sara Querido Conde Patrícia Branco Henrique Sousa Teresa Adragão Augusta Gaspar José Diogo Barata |
| author_facet | Sara Querido Conde Patrícia Branco Henrique Sousa Teresa Adragão Augusta Gaspar José Diogo Barata |
| author_sort | Sara Querido Conde |
| collection | DOAJ |
| description | Abstract Introduction: Secondary hyperparathyroidism is the target of several therapeutic strategies, including the use of cinacalcet. Most studies were done only in hemodialysis patients, with few data from peritoneal dialysis patients. Objective: The aim of our work was to evaluate the effectiveness of cinacalcet in secondary hyperparathyroidism in a one-center peritoneal dialysis patients. Methods: A retrospective study was performed in 27 peritoneal dialysis patients with moderate to severe secondary hyperparathyroidism (PTHi > 500 pg/mL with normal or elevated serum calcium levels) treated with cinacalcet. Demographic, clinical and laboratory parameters at the beginning of cinacalcet therapy, second, fourth, sixth months after and at the time it was finished were analyzed. Results: Patients were under peritoneal dialysis at 30.99 ± 16.58 months and were treated with cinacalcet for 15.6 ± 13.4 months; 21 (77.8%) patients showed adverse gastrointestinal effects; PTHi levels at the beginning of cinacalcet therapy were 1145 ± 449 pg/mL. The last PTHi levels under cinacalcet therapy was 1131 ± 642 pg/mL. PTHi reduction was statistically significant at 2 months after the beginning of cinacalcet (p = 0.007) but not in the following evaluations. Conclusion: It is necessary the development of new forms of cinacalcet presentation, in order to avoid gastrointestinal effects adverse factors and to improve therapeutic adherence. |
| first_indexed | 2024-12-11T20:46:53Z |
| format | Article |
| id | doaj.art-97ca2cccc3fa454ba5a9953e562f31f7 |
| institution | Directory Open Access Journal |
| issn | 2175-8239 |
| language | English |
| last_indexed | 2024-12-11T20:46:53Z |
| publisher | Sociedade Brasileira de Nefrologia |
| record_format | Article |
| series | Brazilian Journal of Nephrology |
| spelling | doaj.art-97ca2cccc3fa454ba5a9953e562f31f72022-12-22T00:51:21ZengSociedade Brasileira de NefrologiaBrazilian Journal of Nephrology2175-8239391424510.5935/0101-2800.20170007S0101-28002017000100042Cinacalcet in peritoneal dialysis patients: one-center experienceSara Querido CondePatrícia BrancoHenrique SousaTeresa AdragãoAugusta GasparJosé Diogo BarataAbstract Introduction: Secondary hyperparathyroidism is the target of several therapeutic strategies, including the use of cinacalcet. Most studies were done only in hemodialysis patients, with few data from peritoneal dialysis patients. Objective: The aim of our work was to evaluate the effectiveness of cinacalcet in secondary hyperparathyroidism in a one-center peritoneal dialysis patients. Methods: A retrospective study was performed in 27 peritoneal dialysis patients with moderate to severe secondary hyperparathyroidism (PTHi > 500 pg/mL with normal or elevated serum calcium levels) treated with cinacalcet. Demographic, clinical and laboratory parameters at the beginning of cinacalcet therapy, second, fourth, sixth months after and at the time it was finished were analyzed. Results: Patients were under peritoneal dialysis at 30.99 ± 16.58 months and were treated with cinacalcet for 15.6 ± 13.4 months; 21 (77.8%) patients showed adverse gastrointestinal effects; PTHi levels at the beginning of cinacalcet therapy were 1145 ± 449 pg/mL. The last PTHi levels under cinacalcet therapy was 1131 ± 642 pg/mL. PTHi reduction was statistically significant at 2 months after the beginning of cinacalcet (p = 0.007) but not in the following evaluations. Conclusion: It is necessary the development of new forms of cinacalcet presentation, in order to avoid gastrointestinal effects adverse factors and to improve therapeutic adherence.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002017000100042&lng=en&tlng=enCalcimimetic agentshyperparathyroidism, secondarykidney failure, chronicperitoneal dialysis |
| spellingShingle | Sara Querido Conde Patrícia Branco Henrique Sousa Teresa Adragão Augusta Gaspar José Diogo Barata Cinacalcet in peritoneal dialysis patients: one-center experience Brazilian Journal of Nephrology Calcimimetic agents hyperparathyroidism, secondary kidney failure, chronic peritoneal dialysis |
| title | Cinacalcet in peritoneal dialysis patients: one-center experience |
| title_full | Cinacalcet in peritoneal dialysis patients: one-center experience |
| title_fullStr | Cinacalcet in peritoneal dialysis patients: one-center experience |
| title_full_unstemmed | Cinacalcet in peritoneal dialysis patients: one-center experience |
| title_short | Cinacalcet in peritoneal dialysis patients: one-center experience |
| title_sort | cinacalcet in peritoneal dialysis patients one center experience |
| topic | Calcimimetic agents hyperparathyroidism, secondary kidney failure, chronic peritoneal dialysis |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002017000100042&lng=en&tlng=en |
| work_keys_str_mv | AT saraqueridoconde cinacalcetinperitonealdialysispatientsonecenterexperience AT patriciabranco cinacalcetinperitonealdialysispatientsonecenterexperience AT henriquesousa cinacalcetinperitonealdialysispatientsonecenterexperience AT teresaadragao cinacalcetinperitonealdialysispatientsonecenterexperience AT augustagaspar cinacalcetinperitonealdialysispatientsonecenterexperience AT josediogobarata cinacalcetinperitonealdialysispatientsonecenterexperience |